Pegnano (pegylated interferon-α-2a biosimilar)
/ Nanogen Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 11, 2025
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
(clinicaltrials.gov)
- P4 | N=100 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
New P4 trial • Hepatitis C • Hepatology • Infectious Disease • Inflammation
1 to 1
Of
1
Go to page
1